Surfactant protein (sp)-a and sp-d as antimicrobial and immuno-therapeutic agents

Recent Patents on Anti-Infective Drug Discovery

Volumn 5, Issue 2, 2010, Pages 115-123

  Awasthi, Shanjana ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

Antiinflammatory; Antimicrobial; Bronchopulmonary dysplasia; Host defense; Infection; Inflammation; Innate immunity; Respiratory distress syndrome; Surfactant protein a; Surfactant protein d

Indexed keywords

ANTIINFECTIVE AGENT; CORTICOSTEROID; RECOMBINANT PROTEIN; RECOMBINANT SURFACTANT PROTEIN A; RECOMBINANT SURFACTANT PROTEIN D; SURFACTANT PROTEIN A; SURFACTANT PROTEIN D; UNCLASSIFIED DRUG;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ANTIMICROBIAL ACTIVITY; ARTICLE; ARTIFICIAL VENTILATION; ASTHMA; ATHEROSCLEROSIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; DENDRITIC CELL; DRUG COST; DRUG STRUCTURE; HOMEOSTASIS; HOST RESISTANCE; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; IMMUNOTHERAPY; INNATE IMMUNITY; LIPID OXIDATION; LUNG ALVEOLUS EPITHELIUM; LUNG DISEASE; LUNG DYSPLASIA; LUNG EMPHYSEMA; LUNG INFECTION; MOLECULAR WEIGHT; NONHUMAN; PATENT; PNEUMONIA; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RESPIRATORY DISTRESS; SEPSIS; SIGNAL TRANSDUCTION; SKIN DISEASE;

ANIMALS; ANTI-INFECTIVE AGENTS; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION; LUNG DISEASES; PATENTS AS TOPIC; PULMONARY SURFACTANT-ASSOCIATED PROTEIN A; PULMONARY SURFACTANT-ASSOCIATED PROTEIN D; PULMONARY SURFACTANTS; RECOMBINANT PROTEINS; SURFACE-ACTIVE AGENTS;

EID: 77954039853     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489110791233559     Document Type: Article

References (150)

1. King RJ, Clements JA. Surface active materials from dog lung. II. Composition and physiological correlations. Am J Physiol 1972; 223: 715-26.
2. Wright JR. Immunomodulatory functions of surfactant. Physiol Rev 1997; 77: 931-62.
3. Wright JR. Host defense functions of pulmonary surfactant. Biol Neonate 2004; 85: 326-32.
4. van de Wetering JK, van Golde LM, Batenburg JJ. Collectins: Players of the innate immune system. Eur J Biochem 2004; 271: 1229-49.
5. Crouch EC. Modulation of host-bacterial interactions by collectins. Am J Respir Cell Mol Biol 1999; 21: 558-61.
6. Crouch EC. Collectins and pulmonary host defense. Am J Respir Cell Mol Biol 1998; 19: 177-201.
7. Awasthi S, Coalson JJ, Crouch E, Yang F, King RJ. Surfactant proteins A and D in premature baboons with chronic lung injury (Bronchopulmonary dysplasia). Evidence for an inhibition of secretion. Am J Respir Crit Care Med 1999; 160: 942-9.
8. Wright JR, Borchelt JD, Hawgood S. Lung surfactant apoprotein SP-A (26-36 kDa) binds with high affinity to isolated alveolar type II cells. Proc Natl Acad Sci USA 1989; 86: 5410-4.
9. Young SL, Wright JR, Clements JA. Cellular uptake and processing of surfactant lipids and apoprotein SP-A by rat lung. J Appl Physiol 1989; 66: 1336-42.
10. Wright JR, Hawgood S. Pulmonary surfactant metabolism. Clin Chest Med 1989; 10: 83-93.
11. Wright JR, Wager RE, Hamilton RL, Huang M, Clements JA. Uptake of lung surfactant subfractions into lamellar bodies of adult rabbit lungs. J Appl Physiol 1986; 60: 817-25.
12. Dobbs LG, Wright JR, Hawgood S, Gonzalez R, Venstrom K, Nellenbogen J. Pulmonary surfactant and its components inhibit secretion of phosphatidylcholine from cultured rat alveolar type II cells. Proc Natl Acad Sci USA 1987; 84: 1010-4.
13. Ross GF, Notter RH, Meuth J, Whitsett JA. Phospholipid binding and biophysical activity of pulmonary surfactant-associated protein (SAP)-35 and its non-collagenous COOH-terminal domains. J Biol Chem 1986; 261: 14283-91.
14. Korfhagen TR, Bruno MD, Ross GF, Huelsman KM, Ikegami M, Jobe AH, et al. Altered surfactant function and structure in SP-A gene targeted mice. Proc Natl Acad Sci USA 1996; 93: 9594-9.
15. Botas C, Poulain F, Akiyama J, Brown C, Allen L, Goerke J, et al. Altered surfactant homeostasis and alveolar type II cell morphology in mice lacking surfactant protein D. Proc Natl Acad Sci USA 1998; 95: 11869-74.
16. Hawgood S, Ochs M, Jung A, Akiyama J, Allen L, Brown C, et al. Sequential targeted deficiency of SP-A and -D leads to progressive alveolar lipoproteinosis and emphysema. Am J Physiol Lung Cell Mol Physiol 2002; 283: L1002-10.
17. Pastva AM, Wright JR, Williams KL. Immunomodulatory roles of surfactant proteins A and D: Implications in lung disease. Proc Am Thorac Soc 2007; 4: 252-7.
18. Waters P, Vaid M, Kishore U, Madan T. Lung surfactant proteins A and D as pattern recognition proteins. Adv Exp Med Biol 2009; 653: 74-97.
19. Wu H, Kuzmenko A, Wan S, Schaffer L, Weiss A, Fisher JH, et al. Surfactant proteins A and D inhibit the growth of Gram-negative bacteria by increasing membrane permeability. J Clin Invest 2003; 111: 1589-602.
20. McCormack FX, Gibbons R, Ward SR, Kuzmenko A, Wu H, Deepe GS, Jr. Macrophage-independent fungicidal action of the pulmonary collectins. J Biol Chem 2003; 278: 36250-6.
21. Crouch E, Wright JR. Surfactant proteins A and D and pulmonary host defense. Annu Rev Physiol 2001; 63: 521-54.
22. Mikerov AN, Haque R, Gan X, Guo X, Phelps DS, Floros J. Ablation of SP-A has a negative impact on the susceptibility of mice to Klebsiella pneumoniae infection after ozone exposure: Sex differences. Respir Res 2008; 9: 77.
23. Giannoni E, Sawa T, Allen L, Wiener-Kronish J, Hawgood S. Surfactant proteins A and D enhance pulmonary clearance of Pseudomonas aeruginosa. Am J Respir Cell Mol Biol 2006; 34: 704-10.
24. Ding J, Umstead TM, Floros J, Phelps DS. Factors affecting SP-A-mediated phagocytosis in human monocytic cell lines. Respir Med 2004; 98: 637-50.
25. Kuzmenko AI, Wu H, Wan S, McCormack FX. Surfactant protein A is a principal and oxidation-sensitive microbial permeabilizing factor in the alveolar lining fluid. J Biol Chem 2005; 280: 25913-9.
26. Ferrara A, Dos Santos C, Lupi A. Effect of different antibacterial agents and surfactant protein-A (SP-A) on adherence of some respiratory pathogens to bronchial epithelial cells. Int J Antimicrob Agents 2001; 17: 401-5.
27. Samten B, Townsend JC, Sever-Chroneos Z, Pasquinelli V, Barnes PF, Chroneos ZC. An antibody against the surfactant protein A (SP-A)-binding domain of the SP-A receptor inhibits T cell-mediated immune responses to Mycobacterium tuberculosis. J Leukoc Biol 2008; 84: 115-23.
28. Mikerov AN, Umstead TM, Gan X, Huang W, Guo X, Wang G, et al. Impact of ozone exposure on the phagocytic activity of human surfactant protein A (SP-A) and SP-A variants. Am J Physiol Lung Cell Mol Physiol 2008; 294: L121-30.
29. Hickman-Davis JM, O'Reilly P, Davis IC, Peti-Peterdi J, Davis G, Young KR, et al. Killing of Klebsiella pneumoniae by human alveolar macrophages. Am J Physiol Lung Cell Mol Physiol 2002; 282: L944-56.
30. Sano H, Kuronuma K, Kudo K, Mitsuzawa H, Sato M, Murakami S, et al. Regulation of inflammation and bacterial clearance by lung collectins. Respirology 2006; 11 Suppl: S46-50.
31. Hogenkamp A, Herias MV, Tooten PC, Veldhuizen EJ, Haagsman HP. Effects of surfactant protein D on growth, adhesion and epithelial invasion of intestinal Gram-negative bacteria. Mol Immunol 2007; 44: 3517-27.
32. Sahly H, Ofek I, Podschun R, Brade H, He Y, Ullmann U, et al. Surfactant protein D binds selectively to Klebsiella pneumoniae lipopolysaccharides containing mannose-rich O-antigens. J Immunol 2002; 169: 3267-74.
33. Torrelles JB, Azad AK, Henning LN, Carlson TK, Schlesinger LS. Role of C-type lectins in mycobacterial infections. Curr Drug Targets 2008; 9: 102-12.
34. Griese M. Respiratory syncytial virus and pulmonary surfactant. Viral Immunol 2002; 15: 357-63.
35. van Iwaarden JF, van Strijp JA, Ebskamp MJ, Welmers AC, Verhoef J, van Golde LM. Surfactant protein A is opsonin in phagocytosis of Herpes simplex virus type 1 by rat alveolar macrophages. Am J Physiol 1991; 261: L204-9.
36. Hartshorn KL, White MR, Tecle T, Sorensen GL, Holmskov U, Crouch EC. Viral aggregating and opsonizing activity in collectin trimers. Am J Physiol Lung Cell Mol Physiol 2010; 298(1): L79-88.
37. Doss M, White MR, Tecle T, Gantz D, Crouch EC, Jung G, et al. Interactions of alpha-, beta-, and theta-defensins with influenza A virus and surfactant protein D. J Immunol 2009; 182: 7878-87.
38. Brummer E, Stevens DA. Collectins and fungal pathogens: Roles of surfactant proteins and mannose binding lectin in host resistance. Med Mycol 2009: 1-13.
39. Singh M, Madan T, Waters P, Sonar S, Singh SK, Kamran MF, et al. Therapeutic effects of recombinant forms of full-length and truncated human surfactant protein D in a murine model of invasive pulmonary aspergillosis. Mol Immunol 2009; 46: 2363-9.
40. Erpenbeck VJ, Malherbe DC, Sommer S, Schmiedl A, Steinhilber W, Ghio AJ, et al. Surfactant protein D increases phagocytosis and aggregation of pollen-allergen starch granules. Am J Physiol Lung Cell Mol Physiol 2005; 288: L692-8.
41. Deb R, Shakib F, Reid K, Clark H. Major house dust mite allergens Dermatophagoides pteronyssinus 1 and Dermatophagoides farinae 1 degrade and inactivate lung surfactant proteins A and D. J Biol Chem 2007; 282: 36808-19.
42. Awasthi S, Wolf R, White G. Ontogeny and phagocytic function of baboon lung dendritic cells. Immunol Cell Biol 2009; 87: 419-27.
43. Haczku A. Protective role of the lung collectins surfactant protein A and surfactant protein D in airway inflammation. J Allergy Clin Immunol 2008; 122: 861-79; quiz 80-1.
44. Hu QJ, Xiong SD, Zhang HL, Shi XM, Xu YJ, Zhang ZX, et al. Altered surfactant protein A gene expression and protein homeostasis in rats with emphysematous changes. Chin Med J (Engl) 2008; 121: 1177-82.
45. Hu Q, Zhang H, Xiong S, Shi X, Xu Y, Zhang Z, et al. The alteration and significance of surfactant protein A in rats chronically exposed to cigarette smoke. J Huazhong Univ Sci Technolog Med Sci 2008; 28: 128-31.
46. Honda Y, Takahashi H, Kuroki Y, Akino T, Abe S. Decreased contents of surfactant proteins A and D in BAL fluids of healthy smokers. Chest 1996; 109: 1006-9.
47. Vlachaki EM, Koutsopoulos AV, Tzanakis N, Neofytou E, Siganaki M, Drositis I, et al. Altered Surfactant Protein-A (SP-A) Expression in Type Ii Pneumocytes in Copd. Chest 2010; 137(1): 37-45.
48. Behera D, Balamugesh T, Venkateswarlu D, Gupta A, Majumdar S. Serum surfactant protein-A levels in chronic bronchitis and its relation to smoking. Ind J Chest Dis Allied Sci 2005; 47: 13-7.
49. Sin DD, Pahlavan PS, Man SF. Surfactant protein D: A lung specific biomarker in COPD? Ther Adv Respir Dis 2008; 2: 65-74.
50. Sin DD, Man SF, McWilliams A, Lam S. Surfactant protein D and bronchial dysplasia in smokers at high risk of lung cancer. Chest 2008; 134: 582-8.
51. Lomas DA, Silverman EK, Edwards LD, Locantore NW, Miller BE, Horstman DH, et al. Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. Eur Respir J 2009; 34: 95-102.
52. Betsuyaku T, Kuroki Y, Nagai K, Nasuhara Y, Nishimura M. Effects of ageing and smoking on SP-A and SP-D levels in bronchoalveolar lavage fluid. Eur Respir J 2004; 24: 964-70.
53. Erpenbeck VJ, Ziegert M, Cavalet-Blanco D, Martin C, Baelder R, Glaab T, et al. Surfactant protein D inhibits early airway response in Aspergillus fumigatus-sensitized mice. Clin Exp Allergy 2006; 36: 930-40.
54. Cheng G, Ueda T, Numao T, Kuroki Y, Nakajima H, Fukushima Y, et al. Increased levels of surfactant protein A and D in bronchoalveolar lavage fluids in patients with bronchial asthma. Eur Respir J 2000; 16: 831-5.
55. Erpenbeck VJ, Schmidt R, Gunther A, Krug N, Hohlfeld JM. Surfactant protein levels in bronchoalveolar lavage after segmental allergen challenge in patients with asthma. Allergy 2006; 61: 598-604.
56. D'Ovidio F, Mura M, Ridsdale R, Takahashi H, Waddell TK, Hutcheon M, et al. The effect of reflux and bile acid aspiration on the lung allograft and its surfactant and innate immunity molecules SP-A and SP-D. Am J Transplant 2006; 6: 1930-8.
57. Erasmus ME, Hofstede GJ, Petersen AH, Batenburg JJ, Haagsman HP, Oetomo SB, et al. SP-A-enriched surfactant for treatment of rat lung transplants with SP-A deficiency after storage and reperfusion. Transplantation 2002; 73: 348-52.
58. Tagaram HR, Wang G, Umstead TM, Mikerov AN, Thomas NJ, Graff GR, et al. Characterization of a human surfactant protein A1 (SP-A1) gene-specific antibody; SP-A1 content variation among individuals of varying age and pulmonary health. Am J Physiol Lung Cell Mol Physiol 2007; 292: L1052-63.
59. Griese M, Essl R, Schmidt R, Rietschel E, Ratjen F, Ballmann M, et al. Pulmonary surfactant, lung function, and endobronchial inflammation in cystic fibrosis. Am J Respir Crit Care Med 2004; 170: 1000-5.
60. Korfhagen TR. Surfactant protein A (SP-A)-mediated bacterial clearance: SP-A and cystic fibrosis. Am J Respir Cell Mol Biol 2001; 25: 668-72.
61. Bai Y, Galetskiy D, Damoc E, Paschen C, Liu Z, Griese M, et al. High resolution mass spectrometric alveolar proteomics: identification of surfactant protein SP-A and SP-D modifications in proteinosis and cystic fibrosis patients. Proteomics 2004; 4: 2300-9.
62. Starosta V, Griese M. Oxidative damage to surfactant protein D in pulmonary diseases. Free Radic Res 2006; 40: 419-25.
63. Heinrich S, Hartl D, Griese M. Surfactant protein A-from genes to human lung diseases. Curr Med Chem 2006; 13: 3239-52.
64. Pison U, Obertacke U, Seeger W, Hawgood S. Surfactant protein A (SP-A) is decreased in acute parenchymal lung injury associated with polytrauma. Eur J Clin Invest 1992; 22: 712-8.
65. Endo S, Sato N, Nakae H, Yamada Y, Makabe H, Abe H, et al. Surfactant protein A and D (SP-A, AP-D) levels in patients with septic ARDS. Res Commun Mol Pathol Pharmacol 2002; 111: 245-51.
66. Kishore U, Bernal AL, Kamran MF, Saxena S, Singh M, Sarma PU, et al. Surfactant proteins SP-A and SP-D in human health and disease. Arch Immunol Ther Exp (Warsz) 2005; 53: 399-17.
67. Fernandez-Real JM, Chico B, Shiratori M, Nara Y, Takahashi H, Ricart W. Circulating surfactant protein A (SP-A), a marker of lung injury, is associated with insulin resistance. Diabetes Care 2008; 31: 958-63.
68. Pan T, Nielsen LD, Allen MJ, Shannon KM, Shannon JM, Selman M, et al. Serum SP-D is a marker of lung injury in rats. Am J Physiol Lung Cell Mol Physiol 2002; 282: L824-32.
69. Nkadi PO, Merritt TA, Pillers DA. An overview of pulmonary surfactant in the neonate: Genetics, metabolism, and the role of surfactant in health and disease. Mol Genet Metab 2009; 97: 95-101.
70. Griese M, Steinecker M, Schumacher S, Braun A, Lohse P, Heinrich S. Children with absent surfactant protein D in bronchoalveolar lavage have more frequently pneumonia. Pediatr Allergy Immunol 2008; 19: 639-47.
71. Eguchi H, Koyama N, Tanaka T, Kamiya K, Ogawa Y. Surfactant apoprotein A (SP-A) in tracheal aspirates of newborn infants with RDS. Acta Paediatr Jpn 1991; 33: 649-54.
72. Hilgendorff A, Heidinger K, Bohnert A, Kleinsteiber A, Konig IR, Ziegler A, et al. Association of polymorphisms in the human surfactant protein-D (SFTPD) gene and postnatal pulmonary adaptation in the preterm infant. Acta Paediatr 2009; 98: 112-7.
73. Beresford MW, Shaw NJ. Bronchoalveolar lavage surfactant protein A, B, and D concentrations in preterm infants ventilated for respiratory distress syndrome receiving natural and synthetic surfactants. Pediatr Res 2003; 53: 663-70.
74. Ikegami M, Jobe AH, Havill AM. Keratinocyte growth factor increases surfactant pool sizes in premature rabbits. Am J Respir Crit Care Med 1997; 155: 1155-8.
75. Chen CM, Wang LF. High-dose vascular endothelial growth factor increases surfactant protein gene expressions in preterm rat lung. Early Hum Dev 2007; 83: 581-4.
76. Awasthi S, Vivekananda J, Awasthi V, Smith D, King RJ. CTP:phosphocholine cytidylyltransferase inhibition by ceramide via PKC-alpha, p38 MAPK, cPLA2, and 5-lipoxygenase. Am J Physiol Lung Cell Mol Physiol 2001; 281: L108-18.
77. Vivekananda J, Awasthi V, Awasthi S, Smith DB, King RJ. Hepatocyte growth factor is elevated in chronic lung injury and inhibits surfactant metabolism. Am J Physiol Lung Cell Mol Physiol 2000; 278: L382-92.
78. Pryhuber GS, Khalak R, Zhao Q. Regulation of surfactant proteins A and B by TNF-alpha and phorbol ester independent of NF-kappa B. Am J Physiol 1998; 274: L289-95.
79. Andreeva AV, Kutuzov MA, Voyno-Yasenetskaya TA. Regulation of surfactant secretion in alveolar type II cells. Am J Physiol Lung Cell Mol Physiol 2007; 293: L259-71.
80. Awasthi S, Awasthi VD. Regulation of pulmonary surfactant by growth factors and cytokines during lung injury. In: Pandalai S, Ed. Research Signpost 2002; 2: 223-38.
81. Lucas R, Verin AD, Black SM, Catravas JD. Regulators of endothelial and epithelial barrier integrity and function in acute lung injury. Biochem Pharmacol 2009; 77: 1763-72.
82. Ngiam N, Post M, Kavanagh BP. Early growth response factor-1 in acute lung injury. Am J Physiol Lung Cell Mol Physiol 2007; 293: L1089-91.
83. Matalon S, Shrestha K, Kirk M, Waldheuser S, McDonald B, Smith K, et al. Modification of surfactant protein D by reactive oxygen-nitrogen intermediates is accompanied by loss of aggregating activity, in vitro and in vivo. FASEB J 2009; 23: 1415-30.
84. O'Reilly P, Hickman-Davis JM, McArdle P, Young KR, Matalon S. The role of nitric oxide in lung innate immunity: Modulation by surfactant protein-A. Mol Cell Biochem 2002; 234-235: 39-48.
85. Guo CJ, Atochina-Vasserman EN, Abramova E, Foley JP, Zaman A, Crouch E, et al. S-nitrosylation of surfactant protein-D controls inflammatory function. PLoS Biol 2008; 6: e266.
86. Awasthi S, Coalson JJ, Yoder BA, Crouch E, King RJ. Deficiencies in lung surfactant proteins A and D are associated with lung infection in very premature neonatal baboons. Am J Respir Crit Care Med 2001; 163: 389-97.
87. Awasthi S, Magee DM, Coalson JJ. Coccidioides posadasii infection alters the expression of pulmonary surfactant proteins (SP)-A and SP-D. Respir Res 2004; 5: 28.
88. Chaiworapongsa T, Hong JS, Hull WM, Romero R, Whitsett JA. Amniotic fluid concentration of surfactant proteins in intra-amniotic infection. J Matern Fetal Neonatal Med 2008; 21: 663-70.
89. Bruce SR, Atkins CL, Colasurdo GN, Alcorn JL. Respiratory syncytial virus infection alters surfactant protein A expression in human pulmonary epithelial cells by reducing translation efficiency. Am J Physiol Lung Cell Mol Physiol 2009; 297: L559-67.
90. Wu Y, Xu Z, Henderson FC, Ryan AJ, Yahr TL, Mallampalli RK. Chronic Pseudomonas aeruginosa infection reduces surfactant levels by inhibiting its biosynthesis. Cell Microbiol 2007; 9: 1062-72.
91. Griese M, Dietrich P, Potz C, Westerburg B, Bals R, Reinhardt D. Surfactant subfractions during nosocomial infection in ventilated preterm human neonates. Am J Respir Crit Care Med 1996; 153: 398-403.
92. Sims MW, Tal-Singer RM, Kierstein S, Musani AI, Beers MF, Panettieri RA, et al. Chronic obstructive pulmonary disease and inhaled steroids alter surfactant protein D (SP-D) levels: A cross-sectional study. Respir Res 2008; 9: 13.
93. Asabe K, Hashimoto S, Suita S, Sueishi K. Maternal dexamethasone treatment enhances the expression of surfactant apoprotein A in the hypoplastic lung of rabbit fetuses induced by oligohydramnios. J Pediatr Surg 1996; 31: 1369-75.
94. Coe CL, Lubach GR. Developmental consequences of antenatal dexamethasone treatment in nonhuman primates. Neurosci Biobehav Rev 2005; 29: 227-35.
95. Schilling, J.W.J., White, R.T., Cordell, B., Benson, B. J. Recombinant alveolar surfactant protein.WO86003408 (1986).
96. Benson, B., Wright, J.R. Pulmonary administration of pharma-ceutically active substances.WO90007469 (1990).
97. Steinhilber, W., Melchers, K., Schafer, K.P., Whitsett, J.A., Levine, A.M., Korfhagen, T.R. Recombinant SP-A for the treat-ment or prevention of pulmonary infection and inflammation. WO00043026 (2000).
98. McCormack, F.X. Peptides with antioxidant and antimicrobial properties. WO02006301 (2002).
99. Sarma, P.U., Madan, T., Saxena, S. Method of detection of SP-A2 gene variants useful for prediction of predisposition to aspergillosis.US7288376 (2007).
100. Clark, H, Nadesalingam, P., Reid, K.B.M., Strong, P. Molecules. WO03035679 (2003).
101. McAlinden, A., Crouch, E., Sandell, L. Trimerizing polypeptides and their uses. WO2005037852 (2005).
102. Ikegami, M., Whitsett, J.A. Surfactant protein-D for prevention and treatment of lung infections and sepsis. WO2007056195 (2007).
103. Holmskov, U., Sorensen, G.L., Madsen, J., Tornoe, I. Surfactant protein-D and atherosclerosis. WO035683 (2003).
104. Whitsett, J.A. Surfactant protein D for the prevention and diagnosis of pulmonary emphysema.WO00023569 (2000).
105. Cavaco, P., Am, S.M., Silva, C.J. Formulation containing neck domains and/or carbohydrate recognition domains for cosmetic applications, namely for the treatment of keratin fibres like hair. WO2007136286 (2007).
106. LeVine AM, Whitsett JA, Gwozdz JA, Richardson TR, Fisher JH, urhans MS, et al. Distinct effects of surfactant protein A or D deficiency during bacterial infection on the lung. J Immunol 2000; 165: 3934-40.
107. Ledford JG, Goto H, Potts EN, Degan S, Chu HW, Voelker DR, et al. SP-A preserves airway homeostasis during Mycoplasma pneumoniae infection in mice. J Immunol 2009; 182: 7818-27.
108. Famuyide ME, Hasday JD, Carter HC, Chesko KL, He JR, Viscardi RM. Surfactant protein-A limits Ureaplasma-mediated lung inflammation in a murine pneumonia model. Pediatr Res 2009; 66: 162-7.
109. Linke MJ, Ashbaugh AD, Demland JA, Walzer PD. Pneumocystis murina colonization in immunocompetent surfactant protein A deficient mice following environmental exposure. Respir Res 2009; 10: 10.
110. Madan T. Potential of lung surfactant proteins, SP-A and SP-D, and mannan binding lectin for therapy and genetic predisposition to allergic and invasive aspergillosis. Recent Pat Inflamm Allergy Drug Discov 2007; 1: 183-7.
111. Ikegami M, Carter K, Bishop K, Yadav A, Masterjohn E, Brondyk W, et al. Intratracheal recombinant surfactant protein D prevents endotoxin shock in the newborn preterm lamb. Am J Respir Crit Care Med 2006; 173: 1342-7.
112. Sato A, Whitsett JA, Scheule RK, Ikegami M. Surfactant protein-D inhibits lung inflammation caused by ventilation in premature newborn lamb. Am J Respir Crit Care Med 2010 (In Press).
113. Clark H, Palaniyar N, Strong P, Edmondson J, Hawgood S, Reid KB. Surfactant protein D reduces alveolar macrophage apoptosis in vivo. J Immunol 2002; 169: 2892-9.
114. George CL, Goss KL, Meyerholz DK, Lamb FS, Snyder JM. Surfactant-associated protein A provides critical immunoprotection in neonatal mice. Infect Immun 2008; 76: 380-90.
115. Wang G, Guo X, Diangelo S, Thomas NJ, Floros J. Humanized SFTPA1 and SFTPA2 transgenic mice reveal functional divergence of SP-A1 and SP-A2: Formation of tubular myelin in vivo requires both gene products. J Biol Chem 2010 (In Press).
116. Goto H, Ledford JG, Mukherjee S, Noble PW, Williams KL, Wright JR. The role of surfactant protein A in bleomycin-induced acute lung injury. Am J Respir Crit Care Med 2010 (In Press).
117. Moya FR, Sinha SK, D'Agostino R. Surfactant trials. Pediatrics 2006; 117: 245-7; author reply 7-8.
118. Lahra MM, Beeby PJ, Jeffery HE. Intrauterine inflammation, neonatal sepsis, and chronic lung disease: A 13-year hospital cohort study. Pediatrics 2009; 123: 1314-9.
119. Lahra MM, Beeby PJ, Jeffery HE. Maternal versus fetal inflammation and respiratory distress syndrome: A10-year hospital cohort study. Arch Dis Child Fetal Neonatal Ed 2009; 94: F13-6.
120. Li YH, Tullus K. Microbial infection and inflammation in the development of chronic lung disease of prematurity. Microbes Infect 2002; 4: 723-32.
121. Bauer TT, Welte T, Ernen C, Schlosser BM, Thate-Waschke I, de Zeeuw J, et al. Cost analyses of community-acquired pneumonia from the hospital perspective. Chest 2005; 128: 2238-46.
122. Bauer TT, Valencia M, Badia JR, Ewig S, Gonzalez J, Ferrer M, et al. Respiratory microbiology patterns within the first 24 h of ARDS diagnosis: Influence on outcome. Chest 2005; 128: 273-9.
123. Girard TD, Bernard GR. Mechanical ventilation in ARDS: A state-of-the-art review. Chest 2007; 131: 921-9.
124. Calfee CS, Matthay MA. Nonventilatory treatments for acute lung injury and ARDS. Chest 2007; 131: 913-20.
125. Johansson J, Curstedt T, Robertson B. The proteins of the surfactant system. Eur Respir J 1994; 7: 372-91.
126. Lewis JF, Veldhuizen RA. The future of surfactant therapy during ALI/ARDS. Semin Respir Crit Care Med 2006; 27: 377-88.
127. Seger N, Soll R. Animal derived surfactant extract for treatment of respiratory distress syndrome. Cochrane Database Syst Rev 2009: CD007836.
128. Lal MK, Sinha SK. Surfactant respiratory therapy using Surfaxin/sinapultide. Ther Adv Respir Dis 2008; 2: 339-44.
129. Laughon M, Bose C, Moya F, Aschner J, Donn SM, Morabito C, et al. A pilot randomized, controlled trial of later treatment with a peptide-containing, synthetic surfactant for the prevention of bronchopulmonary dysplasia. Pediatrics 2009; 123: 89-96.
130. Sinha SK, Lacaze-Masmonteil T, Valls i Soler A, Wiswell TE, Gadzinowski J, Hajdu J, et al. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. Pediatrics 2005; 115: 1030-8.
131. Moya FR, Gadzinowski J, Bancalari E, Salinas V, Kopelman B, Bancalari A, et al. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics 2005; 115: 1018-29.
132. Pfister RH, Soll R, Wiswell TE. Protein-containing synthetic surfactant versus protein-free synthetic surfactant for the prevention and treatment of respiratory distress syndrome. Cochrane Database Syst Rev 2009: CD006180.
133. Haagsman HP, Hogenkamp A, van Eijk M, Veldhuizen EJ. Surfactant collectins and innate immunity. Neonatology 2008; 93: 288-94.
134. Ghodrat M. Lung surfactants. Am J Health Syst Pharm 2006; 63: 1504-21.
135. Hite RD. Surfactant deficiency in adults. Clin Pulm Med 2002; 9: 39-45.
136. Merritt TA, Turner T, Vaucher Y, Hallman M, Wilson MJ. Outcomes of surfactant-treated infants. Analysis of developmental outcome and the economic impact of surfactant therapy. In: Robertson B, Taeusch HW, Eds. Surfactant therapy for lung disease. New York: Marcel Dekker 1995; 601-20.
137. Been JV, Zimmermann LJ. What's new in surfactant? A clinical view on recent developments in neonatology and paediatrics. Eur J Pediatr 2007; 166: 889-99.
138. Sinha S, Moya F, Donn SM. Surfactant for respiratory distress syndrome: Are there important clinical differences among preparations? Curr Opin Pediatr 2007; 19: 150-4.
139. Truog WE. 21st-century use for surfactant? Pediatrics 2009; 123: 173-4.
140. Turell DC. Advances with surfactant. Emerg Med Clin North Am 2008; 26: 921-8, viii.
141. Leon CG, Tory R, Jia J, Sivak O, Wasan KM. Discovery and development of toll-like receptor 4 (TLR4) antagonists: A new paradigm for treating sepsis and other diseases. Pharm Res 2008; 25: 1751-61.
142. Brauer L, Kindler C, Jager K, Sel S, Nolle B, Pleyer U, et al. Detection of surfactant proteins A and D in human tear fluid and the human lacrimal system. Invest Ophthalmol Vis Sci 2007; 48: 3945-53.
143. Bourbon JR, Chailley-Heu B. Surfactant proteins in the digestive tract, mesentery, and other organs: Evolutionary significance. Comp Biochem Physiol A Mol Integr Physiol 2001; 129: 151-61.
144. MacNeill C, Umstead TM, Phelps DS, Lin Z, Floros J, Shearer DA, et al. Surfactant protein A, an innate immune factor, is expressed in the vaginal mucosa and is present in vaginal lavage fluid. Immunology 2004; 111: 91-9.
145. Wirbelauer J, Speer CP. The role of surfactant treatment in preterm infants and term newborns with acute respiratory distress syndrome. J Perinatol 2009; 29 (Suppl 2): S18-22.
146. Zhang L, Ikegami M, Dey CR, Korfhagen TR, Whitsett JA. Reversibility of pulmonary abnormalities by conditional replacement of surfactant protein D (SP-D) in vivo. J Biol Chem 2002; 277: 38709-13.
147. Zhang L, Hartshorn KL, Crouch EC, Ikegami M, Whitsett JA. Complementation of pulmonary abnormalities in SP-D(-/-) mice with an SP-D/conglutinin fusion protein. J Biol Chem 2002; 277: 22453-9.
148. Yang S, Milla C, Panoskaltsis-Mortari A, Hawgood S, Blazar BR, Haddad IY. Surfactant protein A decreases lung injury and mortality after murine marrow transplantation. Am J Respir Cell Mol Biol 2002; 27: 297-305.
149. LeVine AM, Elliott J, Whitsett JA, Srikiatkhachorn A, Crouch E, DeSilva N, et al. Surfactant protein-D enhances phagocytosis and pulmonary clearance of respiratory syncytial virus. Am J Respir Cell Mol Biol 2004; 31: 193-9.
150. Knudsen L, Ochs M, Mackay R, Townsend P, Deb R, Muhlfeld C, et al. Truncated recombinant human SP-D attenuates emphysema and type II cell changes in SP-D deficient mice. Respir Res 2007; 8: 70.